Welcome to our dedicated page for Sanuwave Health news (Ticker: SNWV), a resource for investors and traders seeking the latest updates and insights on Sanuwave Health stock.
SANUWAVE Health, Inc. reports company developments tied to FDA-cleared and FDA-approved directed-energy systems used in advanced wound care. The company researches, develops and commercializes non-invasive regenerative medicine technologies designed to activate biological responses for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. Its wound care portfolio includes the UltraMIST product line and related product candidates.
Recurring news includes quarterly and annual revenue updates, financial guidance, conference-call materials, medical-device commercialization activity and channel relationships for UltraMIST. Company updates also describe applications of its energy transfer technologies in wound healing, orthopedic and spine, aesthetic and cosmetic, and cardiac and endovascular conditions.
Sanuwave (NASDAQ: SNWV) reported Q2 2026 revenue of $9.7 million, down 3% from $10.1 million in Q2 2025 but slightly above the high end of its revised June 16, 2026 guidance. Gross margin was 76.2% versus 78.1% a year earlier, and operating results moved from income of $1.4 million in Q2 2025 to an operating loss of $0.3 million. Net result shifted from $0.6 million income to a $0.7 million net loss, while Adjusted EBITDA declined to $1.2 million from $3.2 million.
Ultramist® system sales fell to 82 units from 116 a year ago, but Ultramist applicator revenue grew 13% to $7.3 million, accounting for about 75% of revenue. For the first half of 2026, revenue was $19.4 million with a $2.1 million net loss versus a $5.6 million net loss in 2025. Cash and equivalents were $9.4 million at June 30, 2026, with total assets of $36.6 million and stockholders’ equity of $2.8 million. Citing Medicare reimbursement developments and a 2027 CMS proposed rule for code 97610, Sanuwave withdrew its 2026 guidance and will reassess after the final CMS rule expected in Q4 2026.
Sanuwave (NASDAQ: SNWV) announced it will host a live conference call on Friday, August 7, 2026 at 8:30 AM (ET) to present its Q2 2026 financial results. Investors can join via toll-free or international dial-in, or through a webcast link, with materials on the company’s investor website and a replay available until August 21, 2026.
Sanuwave Health (NASDAQ: SNWV) reported preliminary, unaudited revenues of $9.6–$9.8 million for Q2 2026, exceeding the high end of its revised guidance of $8.5–$9.5 million. This compares to revenues of $10.1 million in Q2 2025, a decline of approximately 3–5%.
According to Sanuwave, capital equipment sales faced headwinds from customer stress and used Ultramist system sales. The company highlighted record unit and revenue performance in consumable applicator sales and noted that these results may be adjusted upon completion of its Q2 2026 financial close and review.
Sanuwave Health (NASDAQ:SNWV) updated its Q2 2026 revenue guidance to $8.5–$9.5 million, below guidance discussed on the Q1 2026 earnings call. Management cites weaker capital equipment demand for the Ultramist system.
CMS reimbursement clawbacks are driving wound-care clinic closures and used Ultramist sales, pressuring new-system demand, while applicator consumable volumes are on pace for a record quarter.
Sanuwave (NASDAQ: SNWV) reported Q1 2026 revenue of $9.6 million, up 3.1% year over year and the highest Q1 in company history. Gross margin was 77.3% versus 79.0% in Q1 2025. GAAP operating loss was $1.1 million, with net loss of $1.4 million. Adjusted EBITDA was $1.1 million.
The company sold 97 Ultramist systems, while Ultramist consumables revenue rose 15% to $6.7 million and represented 100% of revenue. Sanuwave forecasts Q2 2026 revenue of $11.1–$11.6 million (10–15% growth) and reiterates 2026 revenue guidance of $51.0–$55.0 million (16–25% growth versus 2025).
Sanuwave (NASDAQ: SNWV) will host a live conference call on May 13, 2026 at 8:30 AM ET to present Q1 2026 financial results. Telephone and webcast access are provided; replay available through May 27, 2026. Materials will be posted at the company investor website.
Dial-in numbers, conference ID, webcast link, and replay details are available for investors to listen live or on replay.
Sanuwave (NASDAQ: SNWV) reported preliminary Q1 2026 revenue of $9.6–$9.7 million, a 3–4% increase versus Q1 2025 and in line with prior guidance. Management said several good-sized deals slipped out of the quarter, and Q1 results are preliminary pending quarter-end close.
CEO noted strong practitioner interest at the SAWC conference and emphasized continued focus on Ultramist amid reimbursement headwinds.
Sanuwave (NASDAQ: SNWV) reported record quarterly and annual revenue: $13.4M in Q4 2025 (+29.7% YoY) and $44.1M for full-year 2025 (+35.0% YoY). Gross margin was 74.7% in Q4 and 77.1% for 2025. GAAP operating income was $2.0M Q4 and $4.9M for 2025. Adjusted EBITDA improved to $4.8M Q4 and $13.6M for 2025. Company guides Q1 2026 revenue of $9.6–10.3M and 2026 revenue of $51.0–55.0M (16–25% growth).
Sanuwave (NASDAQ: SNWV) will host a live conference call on March 27, 2026 at 8:30 AM ET to present Q4 and full year 2025 financial results. Telephone and instant-access webcast details, conference and replay IDs, and investor materials will be available on the company website.
Telephone dial-in, international numbers, and replay instructions are provided; a replay will be available through April 10, 2026.
Sanuwave Health (NASDAQ: SNWV) reported preliminary Q4 2025 revenue of $13.3–$13.4 million, a 29–30% increase versus Q4 2024 and the company’s highest quarterly revenue ever. Full-year 2025 revenue rose to $44.3–$44.4 million, up 36% year-over-year and a record for the company. Management said Q4 results are within prior guidance and are based on preliminary quarter-end analysis that may be adjusted during financial close. The company noted market disruption from reduced reimbursement for skin-substitutes and allografts, and said it is adding partners and sales channels while adapting its business model. Final audited results and further detail will be released with the March earnings report.